NextCure Net Worth
NextCure Net Worth Breakdown | NXTC |
NextCure Net Worth Analysis
NextCure's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including NextCure's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of NextCure's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform NextCure's net worth analysis. One common approach is to calculate NextCure's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares NextCure's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing NextCure's net worth. This approach calculates the present value of NextCure's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of NextCure's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate NextCure's net worth. This involves comparing NextCure's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into NextCure's net worth relative to its peers.
Enterprise Value |
|
To determine if NextCure is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NextCure's net worth research are outlined below:
| NextCure generated a negative expected return over the last 90 days | |
| NextCure may become a speculative penny stock | |
| NextCure has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (62.72 M) with loss before overhead, payroll, taxes, and interest of (54.2 M). | |
| NextCure currently holds about 185.49 M in cash with (52.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| NextCure has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results |
NextCure uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in NextCure. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to NextCure's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know NextCure's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as NextCure is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NextCure backward and forwards among themselves. NextCure's institutional investor refers to the entity that pools money to purchase NextCure's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Federated Hermes Inc | 2024-06-30 | 327.4 K | Acuitas Investments, Llc | 2024-06-30 | 323.3 K | Citadel Advisors Llc | 2024-06-30 | 289.1 K | Bml Capital Management Llc | 2024-09-30 | 276.5 K | Cardiff Park Advisors, Llc | 2024-06-30 | 262 K | Hudson Bay Capital Management Lp | 2024-06-30 | 203.8 K | Geode Capital Management, Llc | 2024-06-30 | 195.9 K | Macquarie Group Ltd | 2024-06-30 | 150 K | Sio Capital Management, Llc | 2024-06-30 | 130 K | Logos Global Management Lp | 2024-06-30 | 5 M | Sofinnova Ventures | 2024-06-30 | 2.7 M |
Follow NextCure's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.09 M.Market Cap |
|
Project NextCure's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.51) | |
| Return On Capital Employed | (0.55) | (0.58) | |
| Return On Assets | (0.48) | (0.51) | |
| Return On Equity | (0.55) | (0.52) |
When accessing NextCure's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures NextCure's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NextCure's profitability and make more informed investment decisions.
Please note, the presentation of NextCure's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NextCure's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of NextCure's management manipulating its earnings.
Evaluate NextCure's management efficiency
NextCure has return on total asset (ROA) of (0.3109) % which means that it has lost $0.3109 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5475) %, meaning that it created substantial loss on money invested by shareholders. NextCure's management efficiency ratios could be used to measure how well NextCure manages its routine affairs as well as how well it operates its assets and liabilities. As of November 11, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.58. At present, NextCure's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 200.8 M, whereas Net Tangible Assets are forecasted to decline to about 173.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.11 | 4.87 | |
| Tangible Book Value Per Share | 4.11 | 4.87 | |
| Enterprise Value Over EBITDA | (0.39) | (0.41) | |
| Price Book Value Ratio | 0.28 | 0.29 | |
| Enterprise Value Multiple | (0.39) | (0.41) | |
| Price Fair Value | 0.28 | 0.29 | |
| Enterprise Value | 25.3 M | 24 M |
Understanding the operational decisions made by NextCure management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 1.623 | Quarterly Revenue Growth (1.00) | Return On Equity (0.55) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NextCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on NextCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NextCure insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jones Elaine V over a month ago Acquisition by Jones Elaine V of 14250 shares of NextCure at 1.62 subject to Rule 16b-3 | ||
Jones Elaine V over two months ago Acquisition by Jones Elaine V of 14250 shares of NextCure at 4.77 subject to Rule 16b-3 | ||
Kabakoff David S over three months ago Acquisition by Kabakoff David S of 28050 shares of NextCure at 1.5 subject to Rule 16b-3 | ||
Cobourn Steven P. over three months ago Acquisition by Cobourn Steven P. of 100000 shares of NextCure at 12.59 subject to Rule 16b-3 | ||
Cobourn Steven P. over six months ago Acquisition by Cobourn Steven P. of 93900 shares of NextCure at 2.23 subject to Rule 16b-3 | ||
Langermann Sol over six months ago Acquisition by Langermann Sol of 117375 shares of NextCure subject to Rule 16b-3 | ||
Nicholson Garry A over a year ago Acquisition by Nicholson Garry A of 14250 shares of NextCure subject to Rule 16b-3 | ||
Langermann Sol over a year ago Acquisition by Langermann Sol of 135000 shares of NextCure subject to Rule 16b-3 |
NextCure Earnings per Share Projection vs Actual
NextCure Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Steven CPA | Chief Officer | Profile | |
| Sebastien Maloveste | Senior Development | Profile | |
| Sourav Kundu | Senior Manufacturing | Profile | |
| Kevin Shaw | General Counsel | Profile | |
| Michael MSBA | CEO, CoFounder | Profile | |
| Lieping MD | CoFounder Board | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.55) |
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.